Lyell Immunopharma (LYEL) Total Current Liabilities (2020 - 2026)
Lyell Immunopharma (LYEL) posted Total Current Liabilities of $36.9 million for Q1 2026, down 25.23% sequentially from $49.4 million in Q4 2025, and down 10.51% YoY from $41.3 million in Q1 2025.
Lyell Immunopharma (LYEL) Total Current Liabilities (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Total Current Liabilities for 7 years, with the latest figure at $36.9 million in Q1 2026.
- Quarterly Total Current Liabilities fell 10.51% year-over-year to $36.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.9 million (down 10.51% YoY) and the FY2025 annual result came in at $49.4 million, down 8.14% from the prior year.
- Total Current Liabilities fell to $36.9 million in Q1 2026 per LYEL's latest filing, from $49.4 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $53.8 million in Q4 2024 and troughed at $30.8 million in Q1 2023.
- A 5-year average of $38.9 million and a median of $36.9 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities tumbled 31.62% in 2023, then soared 55.82% in 2024.
- Over 5 years, Total Current Liabilities stood at $37.0 million in 2022, then fell by 6.78% to $34.5 million in 2023, then soared by 55.82% to $53.8 million in 2024, then retreated by 8.14% to $49.4 million in 2025, then slipped by 25.23% to $36.9 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $36.9 million, $49.4 million, and $31.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 39.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.87 Mn |
| Mar 31, 2026 | 36.95 Mn |
| Dec 31, 2025 | 49.41 Mn |
| Sep 30, 2025 | 31.88 Mn |
| Jun 30, 2025 | 36.90 Mn |
| Mar 31, 2025 | 41.29 Mn |
| Dec 31, 2024 | 53.79 Mn |
| Sep 30, 2024 | 33.51 Mn |
| Jun 30, 2024 | 30.88 Mn |
| Mar 31, 2024 | 32.35 Mn |
| Dec 31, 2023 | 34.52 Mn |
| Sep 30, 2023 | 35.06 Mn |
| Jun 30, 2023 | 34.39 Mn |
| Mar 31, 2023 | 30.80 Mn |
| Dec 31, 2022 | 37.03 Mn |
| Sep 30, 2022 | 51.22 Mn |
| Jun 30, 2022 | 50.29 Mn |
| Mar 31, 2022 | 41.06 Mn |
| Dec 31, 2021 | 46.74 Mn |
| Sep 30, 2021 | 59.28 Mn |